These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

389 related articles for article (PubMed ID: 23636450)

  • 1. MSH3 expression does not influence the sensitivity of colon cancer HCT116 cell line to oxaliplatin and poly(ADP-ribose) polymerase (PARP) inhibitor as monotherapy or in combination.
    Tentori L; Muzi A; Dorio AS; Dolci S; Campolo F; Vernole P; Lacal PM; Praz F; Graziani G
    Cancer Chemother Pharmacol; 2013 Jul; 72(1):117-25. PubMed ID: 23636450
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of MLH1 on colon cancer sensitivity to poly(ADP-ribose) polymerase inhibitor combined with irinotecan.
    Tentori L; Leonetti C; Muzi A; Dorio AS; Porru M; Dolci S; Campolo F; Vernole P; Lacal PM; Praz F; Graziani G
    Int J Oncol; 2013 Jul; 43(1):210-8. PubMed ID: 23653048
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MSH3 mismatch repair protein regulates sensitivity to cytotoxic drugs and a histone deacetylase inhibitor in human colon carcinoma cells.
    Park JM; Huang S; Tougeron D; Sinicrope FA
    PLoS One; 2013; 8(5):e65369. PubMed ID: 23724141
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MSH3 mediates sensitization of colorectal cancer cells to cisplatin, oxaliplatin, and a poly(ADP-ribose) polymerase inhibitor.
    Takahashi M; Koi M; Balaguer F; Boland CR; Goel A
    J Biol Chem; 2011 Apr; 286(14):12157-65. PubMed ID: 21285347
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human colon cancer cells surviving high doses of cisplatin or oxaliplatin in vitro are not defective in DNA mismatch repair proteins.
    Sergent C; Franco N; Chapusot C; Lizard-Nacol S; Isambert N; Correia M; Chauffert B
    Cancer Chemother Pharmacol; 2002 Jun; 49(6):445-52. PubMed ID: 12107548
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MLH1-deficient tumor cells are resistant to lipoplatin, but retain sensitivity to lipoxal.
    Fedier A; Poyet C; Perucchini D; Boulikas T; Fink D
    Anticancer Drugs; 2006 Mar; 17(3):315-23. PubMed ID: 16520660
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Presence of MLH1 protein aggravates the potential of the HSP90 inhibitor radicicol to sensitize tumor cells to cisplatin.
    Fedier A; Stuedli A; Fink D
    Int J Oncol; 2005 Dec; 27(6):1697-705. PubMed ID: 16273226
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination of oxaliplatin and irinotecan on human colon cancer cell lines: activity in vitro and in vivo.
    Guichard S; Arnould S; Hennebelle I; Bugat R; Canal P
    Anticancer Drugs; 2001 Oct; 12(9):741-51. PubMed ID: 11593056
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of DNA mismatch repair in platinum drug resistance.
    Fink D; Nebel S; Aebi S; Zheng H; Cenni B; Nehmé A; Christen RD; Howell SB
    Cancer Res; 1996 Nov; 56(21):4881-6. PubMed ID: 8895738
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemotherapy-induced O(6)-benzylguanine-resistant alkyltransferase mutations in mismatch-deficient colon cancer.
    Liu L; Schwartz S; Davis BM; Gerson SL
    Cancer Res; 2002 Jun; 62(11):3070-6. PubMed ID: 12036916
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Loss of MLH1 sensitizes colon cancer cells to DNA-PKcs inhibitor KU60648.
    Hinrichsen I; Ackermann A; Düding T; Graband A; Filmann N; Plotz G; Zeuzem S; Brieger A
    Mol Carcinog; 2017 Jul; 56(7):1816-1824. PubMed ID: 28224663
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Hippo pathway terminal effector TAZ/WWTR1 mediates oxaliplatin sensitivity in p53 proficient colon cancer cells.
    Slaninová V; Heron-Milhavet L; Robin M; Jeanson L; Aissanou A; Kantar D; Tosi D; Bréhélin L; Gongora C; Djiane A
    BMC Cancer; 2024 May; 24(1):587. PubMed ID: 38741073
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Resistance mechanisms following cisplatin and oxaliplatin treatment of the human teratocarcinoma cell line 2102EP.
    Rennicke A; Voigt W; Mueller T; Fruehauf A; Schmoll HJ; Beyer C; Dempke W
    Anticancer Res; 2005; 25(2A):1147-55. PubMed ID: 15868958
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potential of the Akt inhibitor LY294005 to antagonize the efficacy of Cisplatin against HCT116 tumor cells in a DNA mismatch repair-dependent manner.
    Fedier A; Erdmann R; Boulikas T; Fink D
    Int J Oncol; 2006 Nov; 29(5):1303-10. PubMed ID: 17016665
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of hMLH1, hMSH3, and hMSH6 defects in cisplatin and oxaliplatin resistance: correlation with replicative bypass of platinum-DNA adducts.
    Vaisman A; Varchenko M; Umar A; Kunkel TA; Risinger JI; Barrett JC; Hamilton TC; Chaney SG
    Cancer Res; 1998 Aug; 58(16):3579-85. PubMed ID: 9721864
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Decreased transcription-coupled nucleotide excision repair capacity is associated with increased p53- and MLH1-independent apoptosis in response to cisplatin.
    Stubbert LJ; Smith JM; McKay BC
    BMC Cancer; 2010 May; 10():207. PubMed ID: 20470425
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis, Cytotoxicity, and Mechanistic Investigation of Platinum(IV) Anticancer Complexes Conjugated with Poly(ADP-ribose) Polymerase Inhibitors.
    Xu Z; Li C; Zhou Q; Deng Z; Tong Z; Tse MK; Zhu G
    Inorg Chem; 2019 Dec; 58(23):16279-16291. PubMed ID: 31738050
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ERCC1-XPF deficiency is a predictor of olaparib induced synthetic lethality and platinum sensitivity in epithelial ovarian cancers.
    Mesquita KA; Alabdullah M; Griffin M; Toss MS; Fatah TMAA; Alblihy A; Moseley P; Chan SYT; Rakha EA; Madhusudan S
    Gynecol Oncol; 2019 May; 153(2):416-424. PubMed ID: 30797591
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FANCJ expression predicts the response to 5-fluorouracil-based chemotherapy in MLH1-proficient colorectal cancer.
    Nakanishi R; Kitao H; Fujinaka Y; Yamashita N; Iimori M; Tokunaga E; Yamashita N; Morita M; Kakeji Y; Maehara Y
    Ann Surg Oncol; 2012 Oct; 19(11):3627-35. PubMed ID: 22526901
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acquisition of anticancer drug resistance is partially associated with cancer stemness in human colon cancer cells.
    El Khoury F; Corcos L; Durand S; Simon B; Le Jossic-Corcos C
    Int J Oncol; 2016 Dec; 49(6):2558-2568. PubMed ID: 27748801
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.